Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
MD
MediWound Ltd.
MDWD
Mkt Cap
$153.2M
Volume
26.18K
Next Earnings
November 19th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
MD
MDWD
MD
MediWound Ltd.
MDWD
News
·
MediWound to Report First Quarter 2026 Financial Results
Mkt Cap
$157.6M
Volume
26.18K
Next Earnings
November 19th
Chart
Financials
Earnings
News
About
Insider
Filings
MediWound to Report First Quarter 2026 Financial Results
MediWound Ltd. announced it will release Q1 2026 financial results on May 27, 2026, followed by a conference call at 8:30 a.m. ET. The company will discuss results and provide a corporate update on its enzymatic therapeutics pipeline, including FDA-approved NexoBrid® for burn treatment and late-stage EscharEx® for chronic wound debridement.
GlobeNewswire Inc. · May 7, 2026
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound announced multiple presentations of new preclinical and clinical data for EscharEx at three major wound care conferences in April and May 2026. The data demonstrates EscharEx's superior debridement mechanism compared to SANTYL, improved scar outcomes, and supports the ongoing Phase III VALUE trial in venous leg ulcers, with planned expansion into diabetic foot ulcers and pressure ulcers.
GlobeNewswire Inc. · Apr 7, 2026
Chronic Venous Insufficiency Market to Increase at a CAGR of 9.4% During the Forecast Period (2025–2034) Due to the Launch of Emerging Therapies and Chronic Venous Insufficiency Medical Devices | DelveInsight
The chronic venous insufficiency market is projected to grow from $2.1 billion in 2024 to a larger market by 2034, driven by emerging therapies, medical devices, and increasing prevalence of the condition in aging populations.
GlobeNewswire Inc. · Sep 18, 2025
MediWound Revenue Jumps 43% in Q2
MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.
The Motley Fool · Aug 14, 2025
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
MediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.
GlobeNewswire Inc. · Feb 12, 2025
MediWound shares hold Buy rating from TD Cowen on significant grant - Investing.com
MediWound Ltd. has received a €16.25 million grant from the European Innovation Council, which is expected to accelerate the development of its product EscharEx for Diabetic Foot Ulcers. TD Cowen has maintained a Buy rating on MediWound's stock with a $25.00 price target.
Investing.com · Jul 16, 2024
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program - GlobeNewswire
MediWound Ltd. has been awarded €16.25 million in funding from the European Innovation Council to accelerate the development of its EscharEx® product for treating diabetic foot ulcers, which could significantly impact the lives of millions of patients.
GlobeNewswire Inc. · Jul 16, 2024
MediWound Announces $25 Million Strategic Private Placement Financing - GlobeNewswire
Mölnlycke Health Care, a global leader in wound care solutions, has invested $15 million in MediWound, a company developing next-generation enzymatic therapeutics for tissue repair. The investment will support MediWound's pre-commercial activities and development of manufacturing capabilities for its lead drug, EscharEx.
GlobeNewswire Inc. · Jul 15, 2024
Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket - Sharps ... - Benzinga
Sharps Technology shares jumped 31.7% in pre-market trading after the company announced it received two purchase orders for a total of approximately one million SecureGard syringes for 2024 delivery. Several other stocks also saw significant pre-market movements.
Benzinga · Jul 5, 2024
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 2.50% and 6.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 29, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
MD
MDWD
MediWound Ltd.
Buy
Sell
Market
Limit
Soon
MDWD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any MDWD yet.
Related Tickers
Earnings